natgillin/translations-raw huggingface dataset:
In one embodiment, the compositions comprise, in addition to components A) to F) or instead of E) and/or F), also G) at least one laser absorber, preferably in an amount of 0.01% to 10% by weight, more preferably in an amount of 0.1% to 5% by weight, even more preferably in an amount of 0.5% to 3.5% by weight, based in each case on the overall composition, selected from the group of antimony trioxide, tin oxide, tin orthophosphate, barium titanate, aluminium oxide, copper hydroxyphosphate, copper orthophosphate, potassium copper diphosphate, copper hydroxide, antimony tin oxide, bismuth trioxide and anthraquinone, in which case the levels of the other components are reduced to such an extent that the sum total of all the percentages by weight is always 100. 
Pripravci prema bilo kojem od zahtjeva 1 do 4, naznačeni time što, oni pored komponenata A) do F) ili umjesto E) i/ili F), sadrže također G) 0.01% do 10 težinskih %, u odnosu na ukupni pripravak, najmanje jednog laserskog apsorbera odabranog iz skupine koja sadrži antimonov trioksid, kositrov oksid, kositrov ortofosfat, barijev titanat, aluminijev oksid, bakrov hidroksifosfat, bakrov ortofosfat, kalijev bakrov difosfat, bakrov hidroksid, antimonov kositrov oksid, bizmutov trioksid i antrakinon, u kojem se slučaju razine ostalih komponenti smanjuju do te mjere da je ukupni zbroj svih težinskih postotaka uvijek 100.
A method according to Claim 1 or 19 wherein it is determined whether the selected or prepared mutant GPCR is able to bind a plurality of ligands of the same class as the selecting ligand with a comparable spread and/or rank order of affinity as the parent GPCR. 
Metoda u skladu sa Zahtjevima 1-19 naznačena time da se utvrđuje je li odabrana ili pripremljena mutacija GPCRa sposobna vezati veći broj liganada iste skupine kao što je odabrani ligand koji se na usporediv način rasprostire ifili ima jednaki red sklonosti kao i izvorni GPCR.
A container according to claim 29 or 30, wherein the valve stem (51) contains at least one aperture with a diameter of 0.05-1 mm. 
Spremnik prema zahtjevu 22, pri čemu ventilski sklop sadrži najmanje jedan otvor promjera od 0,05-1 mm.
a discharge pump installed within the storage tank to discharge the LNG to the outside of the cargo tank; and 
prvu struju otparenog plina, nastalog iz ukapljenog zemnog plina u skladišnom spremniku (11), te ispuštenog iz skladišnog spremnika (11);
C3-5 cycloalkyl; or a pharmaceutically acceptable salt, solvate, or hydrate thereof. 
C;.s cikloalkil, ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat.
An isolated antibody or antigen-binding fragment thereof that binds to a lysyl oxidase-like 2 (LOXL2) protein, wherein said antibody or antigen-binding fragment specifically binds to the amino acid sequence of SEQ ID NO: 6 and inhibits the enzymatic activity of the LOXL2 protein, wherein the inhibition is non-competitive. 
Izolirano protutijelo ili njegov za antigen vezni fragment koji se veže za lizil oksidaza-sličan (LOXL2) protein, pri čemu se to protutijelo ili antigen vezni fragment specifično vežu za aminokiselinsku sekvencu SEQ ID NO:6 i inhibiraju enzimatsku aktivnost proteina LOXL2, pri čemu je inhibicija ne-kompetitivna.
A method of preparing the dihydrochloride salt according to claim 1 or 2, wherein hydrochloric acid is added to a compound of formula (I): preferably in suspension, thereby forming said dihydrochloride salt of formula (II): 
Postupak za pripravu dihidrokloridne soli prema zahtjevu 1 ili 2, naznačen time da navedeni postupak sadrži dodavanje klorovodične kiseline u spoj s formulom (1): O Å e
A single immunoglobulin variable domain antibody that binds to CD28, comprising the CDR1 sequence of SEQ ID NO:636, the CDR2 sequence of SEQ ID NO:637, and the CDR3 sequence of SEQ ID NO:638. 
Antitijelo sa jednim imunoglobulinskim varijabilnim domenom koje se vezuje za CD28, koje sadrži CDRI sekvencu sa SEQ ID NO:636, CDR2 sekvencu sa SEQ ID NO:637, i CDR3 sekvencu sa SEQ ID NO:638.
Number of spray guns - 1 
(21) Broj predmeta:
The compound according to claim 1, wherein the compound has formula I-B: wherein, independently for each occurrence: 
Spoj prema patentnom zahtjevu 1, pri čemu je spoj formule I-B: o KK Ci H R* O
partially filling the central heating system with system water, 
POSTUPAK ISPIRANJA SUSTAVA CENTRALNOG GRIJANJA HR P20161264 T1
Process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, said process comprising the following successive steps: preparation of a liquid pharmaceutical composition containing the complex of macrocyclic chelate with a lanthanide, and free macrocyclic chelate that is not under the form of an excipient X[X',L] in which L is the macrocyclic chelate and X and X' are a metal ion, in particular chosen independently from calcium, sodium, zinc and magnesium, and free lanthanide, by mixing a solution of free macrocyclic chelate and of free lanthanide, so as to obtain complexation of the lanthanide by the macrocyclic chelate, the amounts of free macrocyclic chelate and of free lanthanide being such that not all the lanthanide is complexed; 
HR P20140537 T1 PATENTNI ZAHTJEVI Postupak za pripravu tekuće farmaceutske formulacije koja sadrži kompleks makrocikličkog kelata s lantanidom i mol/mol količinu slobodnog makrocikličkog kelata između 0.002% i 0.4%, te navedeni postupak sadrži sljedeće uzastopne korake: b) pripravu tekućeg farmaceutskog pripravka koji sadrži kompleks makrocikličkog kelata s lantanidom, te slobodni makrociklički kelat koji nije u obliku pomoćne tvari X[X',L] gdje L je makrociklički kelati X i X' su metalni ion, naročito odabran neovisno od kalcija, natrija, cinka i magnezija, i slobodnog lantanida, pomoću miješanja otopine slobodnog makrocikličkog kelata i slobodnog lantanida, tako da se dobije kompleksiranje lantanida pomoću makrocikličkog kelata, te su količine slobodnog makrocikličkog kelata i slobodnog lantanida takve da sav lantanid ne kompleksira;
is selected from linear or branched, C1-C20 alkyl groups, or phenyl groups optionally substituted with linear or branched C1-C20 alkyl groups, preferably substituted with one or more methyl, ethyl, iso -propyl groups; or R3 represents a ketoimine group having formula: wherein R' and R", the same as each other, represent a hydrogen atom; 
- Rs je izabran od linearnih ili granatih, C,-C2 alkil grupa, ili fenil grupa izborno supstituiranih s linearnim ili granatim Ci-C29 alkil grupama, poželjno supstituiranim s jednom ili više metil, etil, izo-propil grupa; ili
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
Recently, HIV integrase inhibitors have been accepted into clinical trials for treating AIDS and HIV infection (Neamati Expert. 
Nedavno, inhibitori HIV integraze su prihvaćeni u kliničkim ispitivanjima za terapiju SIDA-e i HIV infekcije (Neamati Expert.
The colour of the bulk solution was slight yellowish in those formulations containing lactose. 
Boja otopina za punjenje bila je blijedo žućkasta u onim oblicima koji sadrže laktozu.
The communication apparatus of claim 1, further comprising a transmitter adapted to transmit data from the event/data recorder to a remote computer. 
Komunikacijski uređaj sukladno zahtjevu 1, naznačen time, da nadalje obuhvaća odašiljač prilagođen za prijenos podataka s uređaja za snimanje događaja/podataka do udaljenog računala.
The solid collected is further triturated with water and dried in vacuo to afford oxo-(1H-pyrrolo[2,3-b]pyridine-3-yl)-acetic acid methyl ester; MH+=335. 
Krutu tvar se skupi daljnjim trituriranjem s vodom i osuši se u vakuumu, čime se dobije metil ester okso-(1H-pirolo[2,3-b]-piridin-3-11)-octene kiseline; MH" = 335.
The method as claimed in claim 1 or 2 or the antibody for use as claimed in claim 3 or 4, in which the tumor-associated antigen comprises an amino acid sequence according to SEQ ID NO: 31. 
Farmaceutski pripravak radi primjene sukladno zahtjevu 1 ili 2, pri čemu antigen povezan s tumorom ima aminokiselinsku sekvencu odabranu iz skupine sastavljene od SEQ ID NO: 2, 58, 59, 60, 68 i 69.
Use of HuLuc63 in the preparation of a medicament, said HuLuc63 being a humanized IgG1 antibody having a heavy chain variable region corresponding to SEQ ID NO:5 and a light chain variable region corresponding to SEQ ID NO:6, for the treatment of multiple myeloma of a human patient, wherein the HuLuc63 is administered in combination with bortezomib and wherein HuLuc63 is administered as an intravenous infusion at a dosage from 2.5 mg/kg to 20 mg/kg and the bortezomib is to be administered as an intravenous infusion at a dosage from 0.2 mg/m2 to 2.0 mg/m2. 
Upotreba HuLuc63 u pripravi lijeka, spomenuti HuLuc63 kao humanizirano antitijelo IgG1 ima varijabilno područje teškog lanca koje odgovara sekvenci SEQ ID NO:5 i varijabilno područje lakog lanca koje odgovara sekvenci SEQ ID NO:6; za liječenje multiplog mijeloma ljudskog pacijenta, gdje se HuLuc63 primijenjuje u kombinaciji s bortezomibom i gdje se HuLuc63 daje kao intravenozna infuzija u dozi od 2.5 mg/kg do20 mg/kg, a bortezomib se treba primijeniti kao intravenozna infuzija u dozi od 0.2 mg/m2 do 2.0 mg/m2.
An antibody, or antigen-binding fragment thereof, according to claim 6, wherein said influenza virus strain that is associated with a pandemic outbreak is selected from the group consisting of: H1N1, H5N1, H5N2, H5N8, H5N9, an H2-based strain, and H9N2. 
Antitijelo, ili njegov dio koji veže antigen, prema zahtjevu 6, naznačeni time da je navedeni soj virusa influence koji je povezan sa izbijanjem pandemije odabran iz skupine koja sadrži: HIN1, HSN1, H5N2, HSN8, HSN9, soj na osnovi H2, i H9N2.
The system of claim 15, wherein the gondola can be raised and lowered with respect to the deck. 
Sustav iz zahtjeva 14, naznačen time da gondola (102) može biti podignuta ili spuštena u odnosu na palubu (106).
The use according to any of claims 9 or 10, wherein the cardiac condition is selected from the group consisting of cardiac arrhythmia, tachycardia, atrial arrhythmia, atrial tachyarrhythmia, atrial fibrillation, sustained atrial fibrillation, non-sustained atrial fibrillation, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, sustained ventricular tachycardia, non-sustained ventricular tachycardia, catecholaminergic polymorphic ventricular tachycardia (CPVT), heart failure, sudden cardiac death and exercise-induced sudden cardiac death. 
Uporaba prema bilo kojem od patentnih zahtjeva 9 ili 10, naznačena time što je srčano stanje izabrano iz grupe koju čine srčana aritmija, tahikardija, atrijalna aritmija, atrijalna tahiaritmija, atrijalna fibrilacija, dugotrajna atrijalna fibrilacija, kratkotrajna atrijalna fibrilacija, ventrikularna aritmija, ventrikularna fibrilacija, ventrikularna tahikardija, dugotrajna ventrikularna tahikardija, kratkotrajna ventrikularna tahikardija, kateholaminergička polimorfna ventrikularna tahikardija (CPVT), srčana insuficijencija, iznenadna srčana smrt i iznenadna srčana smrt izazvana pojačanom fizičkom aktivnošću.
The process as set forth in clause 55, further comprising the step of reacting a compound of formula 4-iv: 
HNNS zN za S02iPr l-2 5 ili njegove soli, naznačen time, da obuhvaća korak reakcije spoja formule 4-iv:
A pharmaceutical composition comprising as active ingredient a compound according to claim 1, optionally together with a pharmaceutically acceptable diluent or carrier. 
Farmaceutski sastav, naznačen time, da kao aktivni sastojak obuhvaća spoj prema bilo kojem zahtjevu 1 do 8, opcijski zajedno s farmaceutskim razrjeđivačem ili nosačem.
which method comprises administering daily, at or before bedtime, for at least about two weeks an effective amount of prednisone contained in a delayed-release dosage form to said patient who had previously been treated with an oral immediate release dosage form of a glucocorticoid, wherein the delayed release dosage form is a tablet or a capsule. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu navedeno liječenje obuhvaća davanje navedenom bolesniku učinkovite količine glukokortikoida sadržane u obliku doziranja s odgođenim otpuštanjem, pri čemu je navedeno liječenje primijenjeno jednom dnevno kroz najmanje dva tjedna.
Use of a delta-like ligand 4 (DII4) antagonist in the manufacture of a medicament for lowering a blood glucose level associated with diabetes mellitus type 1 in a subject, wherein the antagonist blocks an interaction between DII4 and Notch receptor, and wherein the DII4 antagonist is an antibody or fragment thereof that specifically binds hDII4 and blocks DII4-Notch signal pathways, or a fusion protein comprising the extracellular domain of DII4 that is fused to the Fc domain of a human IgG. 
Primjena antagonista liganda sličnog delti 4 (DII4) u proizvodnji lijeka za snižavanje razine glukoze u krvi povezane s dijabetesom melitusom tip 1 u bolesnika, naznačena time, što antagonist blokira interakciju između DII4 i Notch Teceptora, i naznačena time, što je antagonist DII4 antitijelo ili njegov fragment koji konkretno vezuje hDII4 i blokira DII4-Notch signalne puteve, ili fuzijski protein koji se sastoji od izvanstanične domene DII4 koja je spojena s Fc domenom humanog IgG-a.
rheumatic diseases or autoimmune diseases or joint diseases, which coincide with inflammatory, allergic and/or proliferative processes, 
(ii) reumatske bolesti ii autoimune bolesti ili bolesti zglobova, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
resulting in intermediates of formula (4); 
što rezultira dobivanjem intermedijera s formulom (4); [image]
A method according to claim 1 in which the lymphoid cells are peripheral blood lymphocytes extracted from heterologous or autologous blood. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što su limfoidne stanice limfociti iz periferne krvi, izolrani iz heterologne ili autologne krvi.
The product as claimed in claim 8, wherein the glass comprises the constituents below in the following proportions (in wt %): 
Proizvod sukladno zahtjevu 9, naznačen time da staklo sadrži sljedeće sastojke u sljedećim omjerima (težinskim udjelima):
matching (56) said estimated torque-speed transfer function and a torque-speed transfer function computed (55) from said computational model of said borehole equipment (10), and 
- uspoređivanja (56) navedene procijenjene funkcije prijenosa okretnog momenta u brzinu 1 funkcije prijenosa okretnog momenta u brzinu, izračunate (55) iz navedenog računalnog modela navedene opreme za pravljenje bušotina (10), 1
reacting the compound of formula VI with the compound of formula VII W-CH2-A2-R15 (VII) wherein W is a halogen or a sulfonyl ester, and R15 is an amino-protecting group, to give a compound of formula VIII 
reakciji spoja formule VI s spojem formule VII W-CH2-A2-R15 (VII), gdje je W halogen ili sulfonilni ester, a R15 je zaštitna skupina za amino, kako bi se dobilo spoj formule VIII [image],
a communication interface configured to transmit data concerning the measured consumption of utilities to a concentrator; 
- komunikacijskog sučelja (CIM) za prijenos podataka vezano uz izmjerenu potrošnju komunalnih usluga u sabirnik (C);
In one embodiment, the fusion protein of formula (I) is selected from the group consisting of SEQ ID NO. 
Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što se bira iz skupine koju čine SEQ ID NO.
A stable aqueous composition of matter comprising a protein and polyoxyethylene (POE) sorbitan, wherein the composition is free of polysorbate, and wherein the POE sorbitan is present at a concentration of from about 150 parts per million (ppm) to about 10,000 ppm, wherein the composition does not comprise a microsphere. 
HR P20190751 T1 PATENTNI ZAHTJEVI Stabilan predmetni vodeni pripravak, naznačen time, da obuhvaća protein i polioksietilen (POE) sorbitan, pri čemu je POE sorbitan prisutan u koncentraciji od otprilike 150 ppm do 10 000 ppm, te time, da spomenuti pripravak ne sadrži polisorbat.
wherein X, X1, X2, R1, L and Y are as defined in claim 1 . 
I pri čemu X, x!, x", R', Li Y su kako je definirano u zahtjevu 1.
vii) for compounds of formula I wherein B represents S, cyclisation of a compound of formula IIb, wherein A1 to A5, X, W and D are as defined in Claim 1 above. 
N-W-D X pri čemu W i D su kako je definirano u zahtjevu 1; i vii) za spojeve s formulom I pri čemu B predstavlja S, ciklizacijom spoja s formulom IIb, [image] pri čemu A1 do A5, X, W i D su kako je definirano gore u zahtjevu 1.
An additional foil disk with a 0.049 in. (1.24 mm) central hole was inserted into the foil tube on the mouth end of the tobacco. 
Dopunski disk od folije 3a centralnim otvorom od 1.24 mm umetne se u cijev sa folijom na usnom kraju duhana.
The CD19xCD3 bispecific single chain antibody construct for the use of any one of claims 1 to 12, wherein the CD19xCD3 bispecific single chain antibody construct is to be administered in a daily dose of 15µg, 30µg, 60µg, or 90µg per square meter patient body surface area. 
Konstrukt CD19xCD3 bispecifičnog jednolančanog protutijela za uporabu prema zahtjevu 15, naznačen time što se konstrukt CD19xCD3 bispecifičnog jednolančanog protutijela primjenjuje u dnevnoj dozi od 15 ug, 30 ug, 60 ug, ili 90 ug po kvadratnom metru površine tijela pacijenta.
The stereoregular diblock polybutadiene according to claim 1 or 2, wherein, in said stereoregular diblock polybutadiene: 
Stereoregularni diblok polibutadien u skladu s patentnim zahtjevom 1 ili 2, naznačen time što, u navedenom stereoregularnom diblok polibutadienu:
A condition related to diabetes includes, but is not limited to, hyperglycemia, impaired glucose tolerance, insulin resistance, pancreatic beta-cell insufficiency, enteroendocrine cell insufficiency, glucosuria, metabolic acidosis, cataracts, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic coronary artery disease, diabetic cerebrovascular disease, diabetic peripheral vascular disease, metabolic syndrome, hyperlipidemia, atherosclerosis, stroke, hypertension, and obesity. 
Pripravak u skladu sa zahtjevom 35, naznačen time, da služi za liječenje ili prevenciju stanja povezanih s dijabetesom izabranih iz skupine koju čine hiperglikemija, smanjena tolerancija glukoze, inzulinska rezistencija, insuficijencija beta-stanica pankreasa, insuficijencija enteroendokrinih stanica, glikozurija, matabolička acidoza, katarakte, dijabetička nefropatija, dijabetička neuropatija, dijabetička retinopatija, dijabetičko oboljenje srčanih arterija, dijabetička cerebrovaskularna bolest, dijabetička periferna vaskularna bolest, metabolički sindrom, hiperlipidemija, ateroskleroza, udar, hipertenzija i debljina.
The process of claim 1 wherein in the compound of formula (VI) R and R′ together with the nitrogen atom they are linked to form a phthalimido group. 
Postupak iz patentnog zahtjeva 7, naznačen time da u spoju formule (VI) da R and R' zajedno s dušikovim atomom za koji su vezani tvore ftalimidnu skupinu.
This top view shows imaginary center axes 605, 610, 615, 620, 625, 630 of the umbrella strut elements 515, 520, 525, 530, 535, 540 and contact points or contact surfaces 635, 640, 645, 650, 655, 660 between the central holding element 510 and the umbrella strut elements 515, 520, 525, 530, 535, 540 . 
515, 520, 525, 530, 535, 540) redom djeluju kao tlačni element i suprotni tlačni element, tvore dodirnu površinu (425, 430, 435, 440; 635, 640, 645, 650, 655, 660), te su međusobno oslonjeni na njihovoj dodirnoj površini na završetku središnjeg elementa držača (110; 510) orijentiranom prema potpornim elementima kišobrana.
The apparatus of clause 1, wherein the height of the downstream portion inhibits passage therethrough of human fetal stem-like cells. The apparatus of clause 1, wherein at least one of the body, the cover, and the separation element bears a focusing step disposed in and extending substantially completely across the channel on the inlet side of the segregating step, the channel having a greater height on the inlet side of the focusing step than on its outlet side. 
Uređaj prema jednom od patentnih zahtjeva 1 do 4, pri čemu najmanje jedno tijelo (2), poklopac (4), i element (1) odvajanja nosi korak fokusiranja smješten unutra i potpuno se pruža preko kanala na ulaznoj strani koraka odvajanja, kanal ima veću visinu od ulazne strane koraka fokusiranja nego na izlaznoj strani; opcionalno, pri čemu se korak fokusiranja proširuje upravno preko kanala.
The process as claimed in claim 7 wherein the compound of formula (1A) is 1-(3',4'-dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid. 
Postupak kako je prijavljen u patentnom zahtjevu 7, naznačen time da spoj formule (1A) jest 1-(3*,4'-diklor-2- fluor[1,1"-bifenil]-4-1l)-ciklopropankarboksilna kiselina.
A compound according to claim 3, for use in the treatment of diseases related to 5-HT6 receptor. 
Spoj sukladno patentnom zahtjevu 3, radi liječenja bolesti povezanih s 5-HTÂ« receptorom.
The lyophilised anti-tumor composition according to claim 6, wherein said buffering agent is selected from phosphate buffer, citrate buffer, glycine/hydrochloric acid buffer, and mixtures thereof. 
9. Smjesa prema patentnom zahtjevu 8, naznačena time što je navedeno sredstvo za puferiranje izabrano između fosfatnog pufera, citratnog pufera, pufera glicin/klorovodična kiselina i njihovih smjesa.
and R2 may be the same or different and are independently selected from hydrogen, halogen, and substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, and substituted or unsubstituted heterocyclyl, or both R1 and R2 directly bound to a common atom, may be joined to form an oxo group (=O) or a substituted or unsubstituted, saturated or unsaturated 3-10 member ring (including the carbon atom to which R1 and R2 are bound), which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NRa and S; 
i R2 mogu biti jednaki ili drugačiji i neovisno su odabrani od vodika, halogena, i supstituiranog ili nesupstituiranog C1-6 alkila, supstituiranog ili nesupstituiranog alkenila, supstituiranog ili nesupstituiranog alkinila, supstituiranog ili nesupstituiranog cikloalkila, supstituiranog ili nesupstituiranog cikloalkenila, supstituiranog ili nesupstituiranog cikloalkilalkila, i supstituiranog ili nesupstituiranog heterociklila, ili oba R1 i R2 izravno vezani na zajednički atom, mogu biti spojeni da oforme okso skupinu (=O) ili supstituiran ili nesupstituiran, zasićen ili nezasićen 3-10 člani prsten (uključujući atom ugljika na koji se R1 i R2 vežu), koji mogu izborno obuhvatiti jedan ili više heteroatoma koji mogu biti jednaki ili drugačiji se dabiru od iz O, NRa i S;
The 1-thio-D-glucitol compound, or the pharmaceutically acceptable salt thereof, or the hydrate of the compound or the salt according to claim 1 or 2, wherein Ar1 is a phenylene group or a naphthylene group. 
Spoj 1-tio-D-glucitol, ili njegova farmaceutski prihvatljiva sol, ili hidrat spoja ili njegova sol prema zahtjevu 1 ili 2, naznačen time da Ar je fenilen skupina ili naftilen skupina.